Soluble engineered ACE2 has further been successfully used to block COVID‐19 from entering cells by increasing its binding to increased circulating ACE2 levels instead of ACE2 bound to the plasma membrane, contributing to a reduced viral load (Monteil et al., 2020). The gene discussed is ACE2; the disease is COVID-19.